2024
Tailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations
Elghazaly H, Azim H, Rugo H, Cameron D, Swain S, Curigliano G, Harbeck N, Tripathy D, Arun B, Aapro M, Piccart M, Cardoso F, Gligorov J, Elghazawy H, Saghir N, Penault‐Llorca F, Perez E, Poortmans P, Abdelaziz H, El‐Zawahry H, Kassem L, Sabry M, Viale G, Al‐Sukhun S, Gado N, Leung J, Elarab L, Cardoso M, Karim K, Foheidi M, Elmaadawy M, Conte P, Selim A, Kandil A, Kamal R, Paltuev R, Guarneri V, Abulkhair O, Zakaria O, Golshan M, Orecchia R, ElMahdy M, Abdel‐Aziz A, Eldin N. Tailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations. Cancer 2024, 130: 3251-3271. PMID: 38985794, DOI: 10.1002/cncr.35389.Peer-Reviewed Original ResearchBreast cancerNeoadjuvant therapyManagement of early breast cancerEarly breast cancerIndividual patient managementDe-escalation strategiesModified Delphi approachBC expertsPostneoadjuvant treatmentSystemic therapyClinical evidencePatient managementConsensus recommendationsClinical situationsTherapyDe-escalationDelphi approachTherapy outcomeTreatment settingsCancerExpert opinionRecommendationsBreastConsensus
2021
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
Metzger-Filho O, Collier K, Asad S, Ansell PJ, Watson M, Bae J, Cherian M, O’Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans WF, Geyer CE, Loibl S, Stover DG. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. Npj Breast Cancer 2021, 7: 142. PMID: 34764307, PMCID: PMC8586340, DOI: 10.1038/s41523-021-00349-y.Peer-Reviewed Original ResearchTriple-negative breast cancerNeoadjuvant chemotherapyCohort studyBreast cancerInstability scoreGenomic instability scoreGermline BRCA mutation carriersPathologic complete response rateAddition of carboplatinComplete response rateStandard neoadjuvant chemotherapyLymph node statusBRCA mutation carriersGermline BRCA1/2 mutationsNegative breast cancerOverall cohortNode statusTreatment armsHigher oddsMutation carriersBRCA1/2 mutationsResponse rateCarboplatinPARP inhibitorsCancerExploring the impact of exercise and mind–body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery
Knoerl R, Giobbie-Hurder A, Sannes TS, Chagpar AB, Dillon D, Dominici LS, Frank ES, Golshan M, McTiernan A, Rhei E, Tolaney SM, Winer EP, Yung RL, Irwin ML, Ligibel JA. Exploring the impact of exercise and mind–body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery. Supportive Care In Cancer 2021, 30: 2027-2036. PMID: 34648061, DOI: 10.1007/s00520-021-06617-8.Peer-Reviewed Original ResearchConceptsCancer treatment-related symptomsPrehabilitation interventionsTreatment-related symptomsTime of enrollmentImpact of exerciseQuality of lifeBreast cancerGroup participantsPre-operative exerciseBreast cancer surgeryMind-body interventionsCognitive functioningOpportunity trialCancer surgeryOutcome measuresSecondary analysisOne monthSurgeryMeasures of qualityGroup comparisonsCancer diagnosisCancerWomenInterventionSignificant differences119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial
Loibl S, Sikov W, Huober J, Rugo H, Wolmark N, O'Shaughnessy J, Maag D, Untch M, Golshan M, Lorenzo J, Metzger O, Dunbar M, Symmans W, Geyer C. 119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial. Annals Of Oncology 2021, 32: s408. DOI: 10.1016/j.annonc.2021.08.400.Peer-Reviewed Original ResearchSurgical Management of Hereditary Breast Cancer
Berger ER, Golshan M. Surgical Management of Hereditary Breast Cancer. Genes 2021, 12: 1371. PMID: 34573353, PMCID: PMC8470490, DOI: 10.3390/genes12091371.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsChemopreventionFemaleGenetic Predisposition to DiseaseGenetic TestingHereditary Breast and Ovarian Cancer SyndromeHeterozygoteHumansMastectomyMutationPractice Guidelines as TopicProphylactic Surgical ProceduresSalpingo-oophorectomyConceptsHereditary breast cancerBreast cancerGenetic variant carriersSurgical risk reductionSurgical management optionsSurgical managementBreast/ovarian cancer susceptibility geneOvarian cancer susceptibility genesVariant carriersCancer susceptibility genesGenetic testingCancer treatmentCancerRisk reductionSusceptibility genesManagement optionsCancer Awareness and Stigma in Rural Assam India: Baseline Survey of the Detect Early and Save Her/Him (DESH) Program
Pak LM, Purad CC, Nadipally S, Rao MP, Mukherjee S, Hegde SKB, Golshan M. Cancer Awareness and Stigma in Rural Assam India: Baseline Survey of the Detect Early and Save Her/Him (DESH) Program. Annals Of Surgical Oncology 2021, 28: 7006-7013. PMID: 34215953, DOI: 10.1245/s10434-021-10366-7.Peer-Reviewed Original ResearchConceptsCancer screening programsScreening programCervical cancerBaseline surveyAcceptance of screeningRural Indian populationMobile screening programLong-term detrimental effectsOne-thirdOral ulcersPreventable causeCancer awarenessCancer knowledgeCancer patientsCancer symptomsActionable targetsMedical careCancerCancer educationCancer etiologyBetel nutConclusionsThis studyIndian populationCarcinogenic effectsCancer diagnosisSurvival Benefits Associated with Surgery in Patients with Metastatic Breast Cancer by Breast Cancer Subtype
Han H, . T, Yu J, Golshan M, Hsu H, Chu C, Hong Z, Fu C, Chou Y, Dai M, Liao G. Survival Benefits Associated with Surgery in Patients with Metastatic Breast Cancer by Breast Cancer Subtype. Journal Of Cancer Science And Clinical Therapeutics 2021, 05 DOI: 10.26502/jcsct.5079127.Peer-Reviewed Original Research
2017
170P Impact of neoadjuvant therapy (NT) and pathological complete response (pCR) on breast-conserving surgery (BCS) in patients (pts) with breast cancer (BC): A meta-analysis
Criscitiello C, Golshan M, Barry W, Viale G, Wong S, Santangelo M, Curigliano G. 170P Impact of neoadjuvant therapy (NT) and pathological complete response (pCR) on breast-conserving surgery (BCS) in patients (pts) with breast cancer (BC): A meta-analysis. Annals Of Oncology 2017, 28: v50-v51. DOI: 10.1093/annonc/mdx362.020.Peer-Reviewed Original Research
2016
Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?
Criscitiello C, Curigliano G, Burstein H, Wong S, Esposito A, Viale G, Giuliano M, Veronesi U, Santangelo M, Golshan M. Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? European Journal Of Surgical Oncology 2016, 42: 1780-1786. PMID: 27825710, DOI: 10.1016/j.ejso.2016.10.011.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsAxillaBreast NeoplasmsClinical Decision-MakingFemaleGenes, BRCA1Genes, BRCA2Genetic Predisposition to DiseaseHereditary Breast and Ovarian Cancer SyndromeHumansLymph Node ExcisionMastectomyMastectomy, SegmentalMedical OveruseNeoadjuvant TherapyPatient PreferenceSurgical OncologyConceptsBreast conservationNeoadjuvant therapyBreast cancerSystemic therapyPathologic complete response rateComplete response rateBreast conservation ratesEffective systemic treatmentPatient-level variablesInvasive surgical approachNeoadjuvant trialsInoperable patientsSurgical overtreatmentSystemic treatmentSurgical approachSurgical benefitsOncology communityResponse ratePatientsTherapyCancerAggressive optionsMastectomySurgeonsConservation rate
2015
Tumor subtype and race in male breast cancer: A population-based cohort study.
Aydogan F, Sagara Y, Mallory M, Tukenmez M, Golshan M. Tumor subtype and race in male breast cancer: A population-based cohort study. Journal Of Clinical Oncology 2015, 33: 149-149. DOI: 10.1200/jco.2015.33.28_suppl.149.Peer-Reviewed Original ResearchMale breast cancerFemale breast cancerBreast cancerRace/ethnicityProgesterone receptorEstrogen receptorTumor subtypesAsian Pacific IslandersPopulation-based cohort studyEnd Results Program databaseBreast cancer subtypesDistribution of subtypesSEER databaseCohort studyFinal cohortHER2 statusProgram databaseNH blacksHispanic menCancer subtypesPatientsUnknown raceCancerSubtypesMolecular profiling
2014
Genetic Predisposition to Breast Cancer
Golshan M. Genetic Predisposition to Breast Cancer. 2014, 263-264. DOI: 10.1007/978-1-4939-1565-1_66.Peer-Reviewed Original ResearchBreast cancer casesBreast cancerCancer casesInvasive breast cancerCancer-related deathOvarian cancer accountsHereditary breast cancerCancer accountsCommon cancerLifetime riskMutation carriersGenetic predispositionBRCA2 genesCancerWomenAmerican womenPredispositionBRCA1Large proportionBreastDiseaseCases
2013
Distinctive lipid profiles of human breast cancer and adjacent normal tissues by desorption electrospray ionization mass spectrometry imaging.
Caragacianu D, Liu X, Norton I, Ide J, Richardson A, Dillon D, Jolesz F, Golshan M, Agar N. Distinctive lipid profiles of human breast cancer and adjacent normal tissues by desorption electrospray ionization mass spectrometry imaging. Journal Of Clinical Oncology 2013, 31: 1132-1132. DOI: 10.1200/jco.2013.31.15_suppl.1132.Peer-Reviewed Original ResearchBreast conserving surgeryAdjacent normal tissuesBreast cancerNormal tissuesCancer tissuesResidual cancer tissueInvasive breast cancer samplesSuccess of surgeryHuman breast cancerNormal breast tissueBreast cancer samplesConserving surgeryLumpectomy bedFatty acidsHuman tissue sectionsLipid profileHistopathology evaluationOperative procedureCancerous human tissuesAnatomical sitesTumor edgeCancer specimenArachidonic acidBreast tissueCancerManagement of the axilla II
Dominici L, Golshan M. Management of the axilla II. 2013, 441-446. DOI: 10.1201/b13937-44.Peer-Reviewed Original ResearchSystemic therapyBreast cancerTumor biologyIndividual patient's tumor biologyAdjuvant treatment recommendationsPatient's tumor biologyAxillary lymph nodesWhole breast irradiationPatients breast cancerNovel chemotherapeutic agentsEndocrine therapyLocal therapyLymph nodesTreatment recommendationsAromatase inhibitorsRadiation therapyLocal controlTherapyChemotherapeutic agentsAccelerated formsSame periodMethods of evaluationCancerBreast
2010
Can axillary lymph node dissection be omitted in patients with breast cancer and positive sentinel nodes?
Dominici L, Golshan M. Can axillary lymph node dissection be omitted in patients with breast cancer and positive sentinel nodes? Minerva Surgery 2010, 65: 547-54. PMID: 21081866.Peer-Reviewed Original ResearchConceptsBreast cancerSentinel lymphAxillary lymph node dissectionPositive sentinel lymph nodesCompletion axillary dissectionLymph node dissectionPositive axillary nodesPositive sentinel nodesSentinel lymph nodesStandard of careInvasive surgical managementNegative axillaAxillary dissectionAxillary lymphNode dissectionAxillary nodesLymph nodesSentinel nodesSurgical managementSurgical proceduresPatientsLymphCancerDissectionTherapeutic purposesRandomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer.
Sikov W, Perou C, Golshan M, Collyar D, Berry D, Hahn O, Singh B, Hudis C, Winer E. Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer. Journal Of Clinical Oncology 2010, 28: tps110-tps110. DOI: 10.1200/jco.2010.28.15_suppl.tps110.Peer-Reviewed Original Research
2008
Young Breast Cancer Patients Undergoing Breast-Conserving Therapy: Role of BRCA1 and BRCA2
Bafford A, Garber J, Chittenden A, Golshan M. Young Breast Cancer Patients Undergoing Breast-Conserving Therapy: Role of BRCA1 and BRCA2. Methods Of Cancer Diagnosis, Therapy And Prognosis 2008, 1: 483-491. DOI: 10.1007/978-1-4020-8369-3_33.Peer-Reviewed Original ResearchBreast cancerYoung breast cancer patientsTumor suppressor geneBreast-Conserving TherapyInvasive breast cancerBreast cancer patientsCancer-related deathSporadic breast cancerSuppressor geneClassical tumor suppressor geneCancer patientsCommon cancerCancerRole of BRCA1WomenAmerican womenBRCA2BRCA1Cell cycle regulationDNA damageMultiple cellular processesPatientsTherapyDiseaseDiagnosisBreast Pain
Golshan M. Breast Pain. 2008, 345-346. DOI: 10.1007/978-0-387-75246-4_85.Peer-Reviewed Original ResearchBreast painFourth of womenOvarian estrogen productionBreast nodularityBreast symptomsHormonal milieuEstrogen productionCommon complaintPalpable abnormalityProgesterone secretionBreast cancerHormonal changesPainPatientsNodularityCommon typeMensesCancerBreastWomenHyperprolactinemiaCommon patternSymptomsMenstruationAbnormalitiesInvasive Breast Cancer
Golshan M. Invasive Breast Cancer. 2008, 337-339. DOI: 10.1007/978-0-387-75246-4_83.Peer-Reviewed Original Research
2004
Prediction of breast cancer size by ultrasound, mammography and core biopsy
Golshan M, Fung B, Wiley E, Wolfman J, Rademaker A, Morrow M. Prediction of breast cancer size by ultrasound, mammography and core biopsy. The Breast 2004, 13: 265-271. PMID: 15325659, DOI: 10.1016/j.breast.2004.05.005.Peer-Reviewed Original Research